Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 6OTHER 5

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 68Prostatic Neoplasms, Castration-Resistant 6Metastatic Castration-resistant Prostate Cancer 6Neoplasms 4Metastatic Castration Resistant Prostate Cancer 4Urogenital Neoplasms 3Prostate Cancer Metastatic 3Neoplasm Metastasis 3Metastatic Castration-Resistant Prostate Cancer 3Genital Neoplasms, Male 3Breast Neoplasms 3Prostatic Diseases 2Neoplasms by Site 2Genital Diseases, Male 2Carcinoma, Non-Small-Cell Lung 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1NSCLC Harboring NRG1 Fusion 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Hyperaldosteronism 1Colorectal Neoplasms 1Advanced Prostate Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

enzalutamide 14Docetaxel 7radium Ra 223 dichloride 6Abiraterone Acetate 6Prednisone 5darolutamide 4abiraterone 3olaparib 2niraparib 2atezolizumab 2apalutamide 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1Rosuvastatin Calcium 1Radium-223 1Pluvicto 1Pioglitazone 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms, Castration-Resistant × Abiraterone Acetate × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Pfizer

Completed
2,731 enrolled 14 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05520138 2024-09-27

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pfizer

Completed
5,506 enrolled 11 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04844749 2024-02-05

VERACITY

Veru Inc.

Phase 3 Terminated
105 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡